Identification and characterization of a neutralizing monoclonal antibody against botulinum neurotoxin, serotype F, following vaccination with active toxin

Hybridoma

Volumn 16, Issue 5, 1997, Pages 447-456

  Brown, Douglas R ^a   Lloyd, John P ^a,b   Schmidt, James J ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b CEL SCI Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN; EPITOPE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; TOXOID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLOSTRIDIUM BOTULINUM; ENZYME LINKED IMMUNOSORBENT ASSAY; HYBRIDOMA; IMMUNOBLOTTING; MOUSE; NONHUMAN; PEPTIDE MAPPING; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CONFORMATION; PROTEIN ISOLATION; SEROTYPE; VACCINATION;

EID: 0030680101     PISSN: 0272457X     EISSN: None     Source Type: Journal    
DOI: 10.1089/hyb.1997.16.447     Document Type: Article

References (28)

1. Schiavo G, Rossetto O, Tonello F, and Montecucco C: Intracellular targets and metalloprotease activity of tetanus and botulism neurotoxins. Curr Top Microbiol Immunol 1995;195:258-274.
2. Schiavo G, Benfenati F, Poulain B, Rosetto O, Polverino de Laureto P, DasGupta BR, and Montecucco C: Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature 1992;359:832-835.
3. Siegel LS: Human immune response to botulinum pentavalent (ABCDE) toxoid determined by a neutralization test and by an enzyme-linked immunosorbent assay. J Clin Microbiol 1988;26: 2351-2356.
4. Heimsch RC, Champion LA, and Sugiyama H: Botulinal toxin and toxoid as antigens. Proc Soc Exp Biol Med 1970;135:151-154.
5. Minton NP: Molecular genetics of clostridial neurotoxins. Curr Top Microbiol Immunol 1995;195:161-194.
6. Hambleton P, Shone CC, Wilton-Smith P, and Melling J: A possible common antigen on clostridial toxins detected by monoclonal anti-botulinum neurotoxin antibodies. In Bacterial Protein Toxins (Alouf JE, Fehrenbach FJ, Freer JH, and Jeljaszewicz J, eds), Academic Press, London, 1984, pp. 449-450.
7. Tsuzuki K, Yokosawa N, Syuto B, Ohishi I, Fujii N, Kimura K, and Oguma K: Establishment of a monoclonal antibody recognizing an antigenic site common to Clostridium botulinum type B, C1, D, and E toxins and tetanus toxin. Infect Immun 1988;56:898-902.
8. Siegel LS: Evaluation of neutralizing antibodies to type A, B, E, and F botulinum toxins in sera from human recipients of botulinum pentavalent (ABCDE) toxoid. J Clin Microbiol 1989;27:1906-1908.
9. Yang KH, and Sugiyama H: Purification and properties of Clostridium botulinum type F toxin. Appl Microbiol 1975;29:598-603.
10. Reed LJ, and Muench H: A simple method of estimating fifty per cent endpoints. Am J Hyg 1938;27:493-497.
11. f-measurement, and optimized procedure. Anal Biochem 1977;78: 459-482.
12. Fairbanks G, Steck TL, and Wallach DFH: Electrophoretic analysis of the major polypeptides of the human erythrocyte membrane. Biochemistry 1971;10:2606-2617.
13. Towbin H, Staehelin T, and Gordon J: Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 1979;76: 4350-4354.
14. Shone CC, Hambleton P, and Melling J: Inactivation of Clostridium botulinum type A neurotoxin by trypsin and purification of two tryptic fragments. Proteolytic action near the COOH-terminus of the heavy subunit destroys toxin-binding activity. Eur J Biochem 1985;151:75-82.
15. Kozaki S, Togashi S, and Sakaguchi G: Separation of Clostridium botulinum type A derivative toxin into two fragments. Jpn J Med Sci Biol 1981;34:61-68.
16. Clayton MA, Clayton JM, Brown DR, and Middlebrook JL: Pro-tective vaccination by a recombinant fragment of Clostridium botulinum neurotoxin serotype A expressed from a synthetic gene in Escherichia coli. Infect Immun 1995;63:2738-2742.
17. LaPenotiere HF, Clayton MA, and Middlebrook JL: Expression of a large, nontoxic fragment of botulinum, neurotoxin serotype A and its use as an immunogen. Toxicon 1995;33:1383-1386.
18. C polypeptide of type F botulinum neurotoxin: It's potential as a vaccine, abstr. 93. Movement Disorders 1995;10:397.
19. Fairweather MF, Lyness VA, and Maskell DJ: Immunization of mice against tetanus with fragments of tetanus toxin synthesized in Escherichia coli. Infect Immun 1987;55:2541-2545.
20. Whelan SM, Elmore MJ, Bodsworth NJ, Atkinson T, and Minton NP: The complete amino acid sequence of the Clostridium botulinum type-E neurotoxin, derived by nucleotide-sequence analysis of the encoding gene. Eur J Biochem 1992;204:657-667.
21. East AK, Richardson PT, Allaway D, Collins MD, Roberts TA, and Thompson DE: Sequence of the gene encoding type F neurotoxin of Clostridium botulinum. FEMS Microbiol Lett 1992;75:225-230.
22. Simpson LL, Lake P, and Kozaki S: Isolation and characterization of a novel human monoclonal antibody that neutralizes tetanus toxin. J Pharm Exp Ther 1990;254:98-103.
23. Robinson JP, Picklesimer JB, and Puett D: Tetanus toxin. The effect of chemical modifications on toxicity, immunogenicity, and conformation. J Biol Chem 1975;250:7435-7442.
24. Nencioni L, Volpini G, Peppoloni S, Bugnoli M, De Magistris T, Marsili I, and Rappuoli R. Properties of pertussis toxin mutant PT-9K/129G after formaldehyde treatment. Infect Immun 1991;59: 625-630.
25. Anderson TJ, Rivest J, Stell R, Steiger MJ, Cohen H, Thompson PD, and Marsden CD: Botulinum toxin treatment of spasmodic torticollis. J Royal Soc Med 1992;85:524-529.
26. Burgunder J-M. Botulinum toxin in the treatment of focal movement disorders. Schweiz Med Wochenschr 1992;122:1311-1316.
27. Newman NJ, and Lambert SR: Botulinum toxin treatment of supranuclear ocular motility disorders. Neurology 1992;42: 1391-1393.
28. Zwirner P, Murry T, Swenson M, and Woodson GE: Effects of botulinum toxin therapy in patients with adductor spasmodic dysphonia: Effects of botulinum toxin therapy in patients with adductor spasmodic dysphonia: Acoustic, aerodynamic, and videoendoscopic findings. Laryngoscope 1992;102:400-406.